OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1466-1477
Open Access | Times Cited: 6
Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1466-1477
Open Access | Times Cited: 6
Showing 6 citing articles:
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
Taroh Satoh, Philippe Barthélémy, Lucia Nogová, et al.
European Journal of Cancer (2025), pp. 115262-115262
Closed Access
Taroh Satoh, Philippe Barthélémy, Lucia Nogová, et al.
European Journal of Cancer (2025), pp. 115262-115262
Closed Access
A Case Report of Futibatinib-Induced Calciphylaxis
Colin Slaymaker, Haoran Li
Kansas Journal of Medicine (2025) Vol. 18, Iss. 1, pp. 25-27
Open Access
Colin Slaymaker, Haoran Li
Kansas Journal of Medicine (2025) Vol. 18, Iss. 1, pp. 25-27
Open Access
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
Maxim Noeraparast, Katarina Krajina, Renate Pichler, et al.
Cancer Communications (2024) Vol. 44, Iss. 10, pp. 1189-1208
Open Access | Times Cited: 2
Maxim Noeraparast, Katarina Krajina, Renate Pichler, et al.
Cancer Communications (2024) Vol. 44, Iss. 10, pp. 1189-1208
Open Access | Times Cited: 2
Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report
Yoan E. Rodriguez, Maham Shahid, Natalia Badillo, et al.
Cureus (2024)
Open Access
Yoan E. Rodriguez, Maham Shahid, Natalia Badillo, et al.
Cureus (2024)
Open Access
A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
Amanda Long, Ikuo Yamamiya, Michelle Valentine, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 9
Open Access
Amanda Long, Ikuo Yamamiya, Michelle Valentine, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 9
Open Access
